



CERTIFICATE OF MAILING

I hereby certify that this paper or fee is being deposited with the United States Postal Service with sufficient postage as first class mail under 37 C.F.R. 1.8 on the date indicated below and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: March 30, 2004

Paige A. Johnson

1614
Attorney Docket No. 11000.1037c5
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of **Matthew SLEEMAN and J. Greg MURISON**

Group Art Unit: 1614

Serial No. : 10/613,413
Filed : July 3, 2003
For : **FIBROBLAST GROWTH FACTOR RECEPTORS
AND METHODS FOR THEIR USE**

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner For Patents
P O Box 1450
Alexandria, VA 22313-1450

Enclosed for filing in the above-referenced patent application are the following:

1. Information Disclosure Statement;
2. Form PTO/SB/08 listing 48 references;
3. Copies of 48 listed references; and
7. Return-receipt postcard.

The Commissioner is hereby authorized to charge any additional fees, which may be required in connection with the filing of these documents, or credit any overpayment to Deposit Account No. 19-3555. This document is filed in duplicate.

Respectfully submitted,

Janet Sleath
Registration No. 37,007

Date: March 30, 2004
SPECKMAN LAW GROUP

20601



CERTIFICATE OF MAILING

I hereby certify that this correspondence is addressed as set out in §1.1(a) and deposited with the United States Postal Service with sufficient postage as first class mail on the date indicated below and is addressed to: Commissioner for Patents, P O Box 1450, Alexandria, VA 22313-1450.

Date: March 30, 2004

Paige A. Johnson

Attorney Docket No. 11000.1037c5
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Jeroen Demmer and J. Greg Murison

Group Art Unit: 1614

Application No. : 10/613,413

Filed : July 3, 2003

For : **FIBROBLAST GROWTH FACTOR RECEPTORS AND METHODS FOR THEIR USE**

INFORMATION DISCLOSURE STATEMENT

Commissioner For Patents
P O Box 1450
Alexandria, VA 22313-1450


Dear Examiner:

The documents listed on the accompanying form PTO/SB/08 are cited in compliance with the provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98, as amended. Applicant does not concede that the references are "prior art" under 35 U.S.C. § 102 or 103, and specifically reserves the right to antedate such material, as by a showing under 37 C.F.R. § 1.131 or otherwise.

The attached PTO/SB/08 form identifies 48 listed references. Copies of each of the listed references are enclosed herewith for the Examiner's convenience.

This Information Disclosure Statement is being filed prior to receipt of any substantive Office Action and therefore no fee or certification is required.

Respectfully submitted,



Janet Sleath
Registration No. 37,007

Date: March 30, 2004
SPECKMAN LAW GROUP
20601

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of


2

Complete if Known

Application Number	10/613,413
Filing Date	July 3, 2003
First Named Inventor	Matthew Sleeman, et al.
Art Unit	1614
Examiner Name	

Attorney Docket Number

11000.1037c5

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
1					
2					
3					


FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country code ³ -Number ⁴ -Kind Code ⁵ (if known)				
1		WO 98/49302	11-05-1998	Genetics Institute, Inc.		
2		WO 99/10364	03-04-1999	Human Genome Sciences, Inc.		
3		WO 99/21859	05-06-1999	Glaxo Group Limited		
4		WO 01/70977 A2	09-27-2001	Amgen, Inc.		
5		WO 00/24756	05-04-2000	Human Genome Sciences, Inc.		
6		WO 01/49715 A2	07-12-2001	Genentech, Inc.		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
1		MAHER, PAMELA, "p38 Mitogen-activated Protein Kinase Activation is Required for Fibroblast Growth Factor-2-stimulated Cell Proliferation but Not Differentiation", The Journal of Biological Chemistry, June 18, 1999, pp. 17491-17498, Vol. 274, No. 25.	
2		BOUJU, SOPHIE, ET AL., "Molecular cloning and functional expression of a novel human gene encoding two 41-43 kDa skeletal muscle internal membrane proteins", BiochemJ., 1998, pp. 549-556, Vol. 335, Great Britain.	
3		GRUSS, HANS-JÜRGEN, and DOWER, STEPHEN, K., "Tumor Necrosis Factor Ligand Superfamily: Involvement in the Pathology of Malignant Lymphomas", BLOOD, The Journal of the American Society of Hematology, June 15, 1998, pp. 3378-3404, Vol. 85, No. 12.	
4		PIETU, GENEVIÈVE, ET AL., "Novel Gene Transcripts Preferentially Expressed in Human Muscles Revealed by Quantitative Hybridization of a High Density cDNA Array", Genome Research, 1996, 492-503, Vol. 6.	
5		BANNER, DAVID, W., ET AL., "Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNF β Complex: Implications for TNF Receptor Activation", Cell, May 7, 1993, pp. 431-445, Vol. 73.	
6		YASPO, MARIE-LAURE, ET AL., "Cloning of a Novel Human Putative Type Ia Integral Membrane Protein Mapping to 21q22.3", Genomics, April 1, 1998, pp.133-136, Vol. 49.	
7		HATTORI, M., ET AL., GenPept Accession No. CAB90552, submitted May 5, 2000.	
8		PIETU, G., ET AL., GenPept Accession No. AAC78827, submitted 1996.	
9		HAYETTE, S., ET AL., GenPept Accession No. AAC64321, submitted 1998.	
10		BAUER, H., ET AL., GenPept Accession No. AAD09175, submitted 1994.	
11		HEMMATI-BRIVANLOU, A., ET AL., GenPept Accession No. AAB30638 submitted November 3, 1994.	
12		GIVOL, D., GenPept Accession No. CAA41209, submitted February 20, 1991.	
13		SHI, D.L., ET AL., GenPept Accession No. CAA53271, submitted 1993.	
14		KATOH, O., ET AL., GenPept Accession No. AAB25535, submitted 1993.	
15		BACHNER, D., ET AL., GenPept Accession No. CAB65272, submitted 1999.	
16		XU, J., ET AL., GenPept Accession No. AAF03400, submitted 1999.	
17		CABIBBO, A., ET AL., GenPept Accession No. AAF20364, submitted 2000.	
18		ISOGAI, T., ET AL., GenPept Accession No. BAA91786, submitted February 16, 2000.	
19		WILSON, R., ET AL., GenPept Accession No. AAB42225, submitted 1994.	
20		RIBOLDI TUNNICLIFFE, G.R., ET AL., GenPept Accession No. AAC15584, submitted September, 1997.	
21		BOUCHON, A., ET., GenPept Accession No. AAF69825, submitted 2000.	
22		SHIBATA, T., GenPept Accession No. BAA18909, submitted April 8, 1994.	
23		JANG, W., ET AL., GenPept Accession No. AAC83205, submitted 1999.	
24		POUSTKA, A., ET AL., GenPept Accession No. CAB55955, submitted September, 1999.	
25		DEAR, T.N., ET AL., Swiss-Prot Accession No. P14730, submitted 1988.	
26		COGLIEVINA, M., ET A., Swiss-Prot Accession No. P53104, submitted 1997.	
27		WETERMAN, M.A.J., ET AL., Swiss-Prot Accession No. Q14956, submitted 1995.	
28		NAGHPAL, S., ET AL., Swiss-Prot Accession No. Q99969, submitted October, 1997.	
29		POUSTKA, A., ET AL., PIR Accession No. T17265, submitted October 15, 1999.	
29		SHI, D.L., ET AL., PIR Accession No. S38579, submitted November, 1993.	

30	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AA184346, February 17, 1997.
31	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AI119658, September 2, 1998.
32	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AA231415, February 26, 1997.
33	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AA498840, July 1, 1997.
34	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AA636311, 1996.
34	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AI050489, July 9, 1998.
35	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AA921460, April 20, 1998.
36	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AI466595, March 9, 1999.
37	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AI287088, November 24, 1998.
38	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. W77540, June 20, 1996.
39	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AA646983, October 28, 1997.
40	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AI116725, February 13, 1997.
41	MARRA, M., ET AL., The WashU-HHMI Mouse EST Project, Accession No. AA475668, June 18, 1997.
42	KO, M.S.H., ET AL., Systematic analyses of genes expressed in fertilized mouse eggs (The ERATO/Doi Project at Wayne State University), Accession No. C86502, March 11, 1998.



Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.